TE‐EP8‐S CLNs mediated mRNA translation in splenic T cells. (A) The cell types were analyzed by the Cre‐LoxP mouse model, which could express tdTomato protein post Cre‐recombinase mRNA expression to delete the stop cassette. (B) Representative flow dot plots of Td‐Tomato⁺ cells in the splenic cell subpopulations measured by flow cytometry. (C) Transfection quantification of Td‐Tomato⁺ splenic cell subpopulations. Data were presented as mean ± s.d., n=3.

TE‐EP8‐S CLNs mediated mRNA translation in splenic T cells. (A) The cell types were analyzed by the Cre‐LoxP mouse model, which could express tdTomato protein post Cre‐recombinase mRNA expression to delete the stop cassette. (B) Representative flow dot plots of Td‐Tomato⁺ cells in the splenic cell subpopulations measured by flow cytometry. (C) Transfection quantification of Td‐Tomato⁺ splenic cell subpopulations. Data were presented as mean ± s.d., n=3.

Source publication
Article
Full-text available
Unlocking the full potential of mRNA immunotherapy necessitates targeted delivery to specific cell subsets in the spleen. Four‐component lipid nanoparticles (LNPs) utilized in numerous clinical trials are primarily limited in hepatocyte and muscular targeting, highlighting the imperative demand for targeted and simplified non‐liver mRNA delivery sy...